Maze Therapeutics (MAZE) Profit After Tax (2024 - 2026)

Maze Therapeutics has reported Profit After Tax for 3 years, with the latest figure at -$24.2 million in Q1 2026.

• Quarterly Profit After Tax rose 26.16% year-over-year to -$24.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$122.5 million (down 261.47% YoY) and the FY2025 annual result came in at -$131.1 million, down 3950.81% from the prior year.
• Profit After Tax climbed to -$24.2 million in Q1 2026 per MAZE's latest filing, from -$34.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at $139.1 million in Q2 2024 and troughed at -$34.6 million in Q4 2025.
• A 3-year average of -$8.8 million and a median of -$30.1 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2025 and 2026: Profit After Tax slumped 514.43% in 2025, then advanced 26.16% in 2026.
• Over 3 years, Profit After Tax stood at -$5.6 million in 2024, then plunged by 514.43% to -$34.6 million in 2025, then gained by 29.97% to -$24.2 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$24.2 million, -$34.6 million, and -$30.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.